|
WO1988007089A1
(en)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
|
GB8720833D0
(en)
|
1987-09-04 |
1987-10-14 |
Celltech Ltd |
Recombinant dna product
|
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
|
WO1993022332A2
(en)
|
1992-04-24 |
1993-11-11 |
Board Of Regents, The University Of Texas System |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
|
US6491916B1
(en)
|
1994-06-01 |
2002-12-10 |
Tolerance Therapeutics, Inc. |
Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
HU230769B1
(hu)
|
1999-01-15 |
2018-03-28 |
Genentech Inc. |
Módosított effektor-funkciójú polipeptid-változatok
|
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
|
AU2003217912A1
(en)
|
2002-03-01 |
2003-09-16 |
Xencor |
Antibody optimization
|
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US7662925B2
(en)
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US20090068178A1
(en)
|
2002-05-08 |
2009-03-12 |
Genentech, Inc. |
Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
|
|
US20060235208A1
(en)
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
|
WO2004042017A2
(en)
|
2002-10-31 |
2004-05-21 |
Genentech, Inc. |
Methods and compositions for increasing antibody production
|
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
JP2006524039A
(ja)
|
2003-01-09 |
2006-10-26 |
マクロジェニクス,インコーポレーテッド |
変異型Fc領域を含む抗体の同定および作製ならびにその利用法
|
|
AU2004213053C1
(en)
|
2003-02-20 |
2009-07-16 |
Seagen Inc. |
Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
CN1871259A
(zh)
|
2003-08-22 |
2006-11-29 |
比奥根艾迪克Ma公司 |
具有改变的效应物功能的经改进的抗体和制备它的方法
|
|
US7498298B2
(en)
|
2003-11-06 |
2009-03-03 |
Seattle Genetics, Inc. |
Monomethylvaline compounds capable of conjugation to ligands
|
|
EP1737890A2
(en)
|
2004-03-24 |
2007-01-03 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
|
PL1776384T3
(pl)
|
2004-08-04 |
2013-10-31 |
Mentrik Biotech Llc |
WARIANTY REGIONÓW Fc
|
|
EP1627563A1
(en)
|
2004-08-10 |
2006-02-22 |
Academisch Medisch Centrum bij de Universiteit van Amsterdam |
Means and methods for producing a stabilized cell of interest
|
|
KR101270829B1
(ko)
|
2004-09-23 |
2013-06-07 |
제넨테크, 인크. |
시스테인 유전자조작 항체 및 접합체
|
|
US7491390B2
(en)
|
2004-10-15 |
2009-02-17 |
Seattle Genetics, Inc. |
Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
|
|
EP1810035A4
(en)
|
2004-11-10 |
2010-03-17 |
Macrogenics Inc |
GENERATION OF FC ANTIBODY REGIONS FOR EFFECTOR FUNCTION
|
|
ES2408704T3
(es)
|
2005-01-05 |
2013-06-21 |
Biogen Idec Ma Inc. |
Moléculas de unión a Cripto
|
|
WO2006105062A2
(en)
|
2005-03-29 |
2006-10-05 |
Verenium Corporation |
Altered antibody fc regions and uses thereof
|
|
CA2602663A1
(en)
|
2005-03-31 |
2006-10-05 |
Xencor, Inc. |
Fc variants with optimized properties
|
|
WO2006116260A2
(en)
|
2005-04-26 |
2006-11-02 |
Medimmune, Inc. |
Modulation of antibody effector function by hinge domain engineering
|
|
WO2008020827A2
(en)
|
2005-08-01 |
2008-02-21 |
Biogen Idec Ma Inc. |
Altered polypeptides, immunoconjugates thereof, and methods related thereto
|
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
|
EP2011870A4
(en)
|
2006-04-14 |
2010-09-15 |
Medical & Biol Lab Co Ltd |
MUTANT POLYPEPTIDE WITH EFFECTOR FUNCTION
|
|
BRPI0710011A2
(pt)
|
2006-04-14 |
2011-08-02 |
Trubion Pharmaceuticals Inc |
proteìnas de ligação compreendendo articulação de imunoglobulina e regiões fc dotadas de funções efetoras fc alteradas
|
|
SG10201504662WA
(en)
|
2006-06-14 |
2015-07-30 |
Macrogenics Inc |
Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
|
|
KR20140116546A
(ko)
|
2006-10-27 |
2014-10-02 |
제넨테크, 인크. |
항체 및 면역접합체 및 이들의 용도
|
|
WO2008070593A2
(en)
|
2006-12-01 |
2008-06-12 |
Seattle Genetics, Inc. |
Variant target binding agents and uses thereof
|
|
WO2008140603A2
(en)
|
2006-12-08 |
2008-11-20 |
Macrogenics, Inc. |
METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
|
|
FR2912465B1
(fr)
|
2007-02-12 |
2013-08-02 |
Jean Melchior |
Moteur a combustion interne alimente par un melange gazeux homogene pauvre.
|
|
NZ583318A
(en)
|
2007-07-16 |
2012-07-27 |
Genentech Inc |
Humanized anti-cd79b antibodies and immunoconjugates and methods of use
|
|
AU2008304748C1
(en)
|
2007-09-26 |
2014-06-12 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant region
|
|
JP5427348B2
(ja)
|
2007-10-12 |
2014-02-26 |
株式会社医学生物学研究所 |
エフェクター機能が向上した抗体
|
|
RU2476441C2
(ru)
|
2007-10-19 |
2013-02-27 |
Сиэтл Дженетикс, Инк. |
Cd19-связывающие средства и их применение
|
|
SG187517A1
(en)
|
2008-01-31 |
2013-02-28 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
|
AU2010270979B2
(en)
|
2009-06-22 |
2015-04-23 |
Medimmune, Llc |
Engineered Fc regions for site-specific conjugation
|
|
MX391454B
(es)
|
2010-04-15 |
2025-03-05 |
Seagen Inc |
Compuesto de engarce-fármaco para conjugación a una unidad de ligando.
|
|
WO2012020065A1
(en)
|
2010-08-10 |
2012-02-16 |
Glycotope Gmbh |
Fab-glycosylated antibodies
|
|
EP2686345B1
(en)
|
2011-03-16 |
2018-04-25 |
Amgen Inc. |
Fc variants
|
|
CN109517059B
(zh)
|
2011-06-30 |
2023-03-28 |
中外制药株式会社 |
异源二聚化多肽
|
|
EP3680251A1
(en)
|
2011-09-30 |
2020-07-15 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecules for promoting elimination of antigens
|
|
JP6322411B2
(ja)
|
2011-09-30 |
2018-05-09 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
|
ES2945932T3
(es)
|
2011-10-14 |
2023-07-10 |
Seagen Inc |
Pirrolobenzodiazepinas y conjugados dirigidos
|
|
CA2854806A1
(en)
|
2011-11-07 |
2013-05-16 |
Medimmune, Llc |
Multispecific and multivalent binding proteins and uses thereof
|
|
US20130309223A1
(en)
|
2012-05-18 |
2013-11-21 |
Seattle Genetics, Inc. |
CD33 Antibodies And Use Of Same To Treat Cancer
|
|
EP3795215A1
(en)
|
2012-05-30 |
2021-03-24 |
Chugai Seiyaku Kabushiki Kaisha |
Target tissue-specific antigen-binding molecule
|
|
EP2857419B1
(en)
|
2012-05-30 |
2021-01-13 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for eliminating aggregated antigens
|
|
US20140154255A1
(en)
|
2012-11-30 |
2014-06-05 |
Abbvie Biotherapeutics Inc. |
Anti-vegf antibodies and their uses
|
|
KR102447350B1
(ko)
*
|
2013-02-08 |
2022-09-23 |
노파르티스 아게 |
면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위
|
|
RU2687043C2
(ru)
|
2013-04-29 |
2019-05-06 |
Ф. Хоффманн-Ля Рош Аг |
МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
|
JP6744212B2
(ja)
*
|
2013-06-21 |
2020-08-19 |
イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. |
ポリペプチドの酵素的結合
|
|
JP6534615B2
(ja)
|
2013-09-27 |
2019-06-26 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
|
CA2940451A1
(en)
|
2014-03-12 |
2015-09-17 |
Novartis Ag |
Specific sites for modifying antibodies to make immunoconjugates
|
|
LT3129406T
(lt)
|
2014-04-11 |
2019-04-10 |
Medimmune, Llc |
Konjuguoti junginiai, apimantys inžineriniu būdu sukonstruotus cisteino antikūnus
|
|
MX2016012830A
(es)
*
|
2014-04-11 |
2017-01-05 |
Medimmune Llc |
Anticuerpos contra el receptor 2 del factor de crecimiento epidermico humano (her2) biespecificos.
|
|
SG10201811124YA
(en)
*
|
2014-06-20 |
2019-01-30 |
Abgenomics Int Inc |
Her2 antibody-drug conjugates
|
|
SI3900742T1
(sl)
|
2014-09-11 |
2024-10-30 |
Seagen Inc. |
Ciljana dostava zdravilnih snovi, ki vsebujejo terciarne amine
|
|
JP6943760B2
(ja)
|
2014-09-12 |
2021-10-06 |
ジェネンテック, インコーポレイテッド |
抗b7−h4抗体及び免疫複合体
|
|
MX2017003123A
(es)
*
|
2014-09-12 |
2017-05-12 |
Genentech Inc |
Anticuerpos y conjugados modificados geneticamente con cisteina.
|
|
LT3191135T
(lt)
|
2014-09-12 |
2020-11-25 |
Genentech, Inc. |
Anti-her2 antikūnai ir imunokonjugatai
|
|
HK1243629A1
(zh)
|
2014-09-17 |
2018-07-20 |
基因泰克公司 |
包含抗her2抗体和吡咯并苯并二氮杂䓬的免疫缀合物
|
|
US20160074527A1
(en)
*
|
2014-09-17 |
2016-03-17 |
Genentech, Inc. |
Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
|
|
JP7082484B2
(ja)
|
2015-04-01 |
2022-06-08 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
|
CN108064246A
(zh)
|
2015-06-15 |
2018-05-22 |
基因泰克公司 |
抗体和免疫结合物
|
|
EP3310813A1
(en)
|
2015-06-17 |
2018-04-25 |
Novartis AG |
Antibody drug conjugates
|
|
TN2018000112A1
(en)
|
2015-10-29 |
2019-10-04 |
Novartis Ag |
Antibody conjugates comprising toll-like receptor agonist
|
|
TWI812873B
(zh)
|
2015-11-30 |
2023-08-21 |
美商輝瑞股份有限公司 |
用於部位專一性接合之抗體和抗體片段
|
|
TWI605057B
(zh)
|
2015-12-18 |
2017-11-11 |
中外製藥股份有限公司 |
抗肌抑素抗體、含變異fc區之多肽及使用方法
|
|
US20170326249A1
(en)
|
2016-05-10 |
2017-11-16 |
Bristol-Myers Squibb Company |
Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and uses
|
|
WO2018009811A1
(en)
|
2016-07-08 |
2018-01-11 |
Genentech, Inc. |
Use of human epididymis protein 4 (he4) for assessing responsiveness of muc 16-positive cancer treatment
|
|
US11046776B2
(en)
|
2016-08-05 |
2021-06-29 |
Genentech, Inc. |
Multivalent and multiepitopic antibodies having agonistic activity and methods of use
|
|
KR102574659B1
(ko)
|
2016-10-11 |
2023-09-04 |
비온디스 비.브이. |
비선형 자가 희생 링커 및 이의 접합체
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
WO2018148447A1
(en)
|
2017-02-08 |
2018-08-16 |
Adimab, Llc |
Antibody heavy chain variable domains targeting the nkg2d receptor
|